JHU004 Clone 3
The cell line is not validated yet.
JHUi009-A
General
Cell Line |
|
| hPSCreg name | JHUi009-A |
| Cite as: | JHUi009-A |
| Alternative name(s) |
JHU004 Clone 3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 21st May 2025 |
| User feedback | |
Provider |
|
| Generator | Johns Hopkins University (JHU) |
| Owner | Johns Hopkins University (JHU) |
| Distributors | |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA118339863 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 30-34 |
| Ethnicity | White/Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | Unavailable |
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA118339864 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Johns Hopkins University Institutional Review Board |
| Approval number | NA_00085175 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Johns Hopkins University Institutional Review Board |
| Approval number | NA_00085175 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Age of donor (at collection) | 30-34 |
| Collected in | 2014 |
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining
|
| Notes on reprogramming vector detection | Putative hiPSC line passaged until Sendai Virus was no longer detected (using CytoTune I, this after p20) |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Initial Clones were selected and individually expanded based on the morphological appearance of the early clones (high nuclear to cytosolic ratio, tight/compact morphologies) |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | Initially, with accutase and subsequently with TrypLE or EDTA |
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
Morphology pictures
JHU004 C3 BF 20x.tif
Representative JHU004 hiPSC colonies - brightfield images
Note: These cells have been utilized and differentiated very successfully to neural crest-derived and paraxial mesoderm derived vascular smooth muscle cells using the protocols of Cheung et al, 2012.
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| Sox17 Sry box transcription factor |
Yes |
| GATA4 zinc finger transcription factor |
Yes |
| FoxA2 forkhead protein |
Yes |
Protocol or reference
Protocol for trilineage differentiation using STEMdiff.pdf
Protocols for trilineage differentiation
JHU004 C3 Endoderm.jpg
PCR results for selected markers following directed differentiation to endoderm
In vitro directed differentiation
Other
| Marker | Expressed |
| Brachyury - T-box transcription factor T |
Yes |
| Heart and Neural Crest Derivatives Expressed 1 |
Yes |
| NKX2-5 homeobox transcription factor |
Yes |
Protocol or reference
Protocol for trilineage differentiation using STEMdiff.pdf
Protocol for trilineage differentiation
JHU004 C3 Mesoderm.jpg
PCR results following directed differentiation to Mesoderm
In vitro directed differentiation
| Marker | Expressed |
| OTX2 homeobox |
Yes |
| Pax6 paired box TF |
Yes |
| Sox1 transcription factor |
Yes |
Protocol or reference
Protocol for trilineage differentiation using STEMdiff.pdf
Protocol for Trilineage differentiation
JHU004 C3 Ectoderm.jpg
PCR data for selected ectoderm markers present following directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal
Passage number: p27
Karyotyping method:
KaryoStat (ThermoFisher)
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.